Senses Disorder TRIZ Cases

Salt forms scavenge toxic aldehydes via complex formation, reducing cellular damage.

Very low atropine concentrations delay myopia onset and reduce progression while minimizing side effects like pupil dilation.

Engineered fibronectin scaffold proteins bind IL-23 p19 to inhibit inflammatory signaling while PEGylation extends serum half-life.

Disubstituted indole methanones reduce SSAO metabolism to enhance tryptase inhibition efficacy.

Replacing subjective perimetry with GDF15 biomarker detection provides reliable glaucoma severity assessment and precise treatment monitoring.

Diazo bicyclic Smac mimetics inhibit IAP proteins to sensitize cancer cells against treatment resistance.

Phenylpyrimidone compounds target type V phosphodiesterase to treat vascular disorders while minimizing off-target effects that cause adverse reactions.

Segmented piperazine ligands achieve D3 selectivity over homologous D2 receptors, enabling antipsychotic efficacy without extrapyramidal side effects.

A temperature-sensitive gel formulation transitions from liquid to gel at body temperature to sustain release of therapeutic proteins.

S-isoproterenol compounds inhibit angiogenesis via adrenergic receptors, reducing side effects and cost compared to monoclonal antibodies.

Interfering RNAs silence TNFR1 mRNA to treat dry eye without steroid side effects.

ALK1 receptor antagonists target the regulatory system to inhibit angiogenesis while sparing normal physiological processes.

Codon-optimized REP1 nucleic acid molecules increase protein expression levels to correct Rab27a trafficking defects in choroideremia.

Combining EO-BO block copolymers with galactomannans prevents lipid deposition and enhances tear film stability for contact lens disinfection.

Liposomal carriers transport somatostatin analogues across the hemato-retinal barrier, achieving therapeutic concentrations in the retina.

A pharmaceutical composition containing novel peptides improves tear volume and corneal surface smoothness.

Adhesion culture elongates retinal ganglion cell axons to centimeter lengths, resolving the contradiction between clinical applicability and axon length.

Non-ionic surfactant eye drops reduce dry eye signs without immunosuppressant side effects.

Ionizable antimicrobial metal salts release ions within hydrophilic polymer matrices to inhibit microbial adhesion on contact lenses.

Combines a quinoline derivative with an S1P receptor modulator to treat inflammatory diseases.

Converting the free base to crystalline fumarate or maleate salts raises melting points and bioavailability for oral administration.

Angiopoietin-like protein 7 stimulates epithelial cell proliferation and neurite formation to restore corneal sensitivity after surgical damage.

Fused imidazo pyrazine derivatives modulate human TNFα activity, expanding therapeutic options beyond macromolecular inhibitors.

Novel peptides increase tear secretion and promote corneal recovery, addressing dry eye side effects.

Antibodies block Nogo-66 binding to promote axonal regeneration in injured central nervous systems.

Spiro neurosteroid compounds protect neural cells from apoptosis without endocrine side effects by modifying the steroid nucleus.

Segmented ocular drops and oral supplements address persistent dry eye symptoms by enhancing acetylcholine availability at lacrimal gland receptors.

VCP inhibitors stabilize photoreceptors to treat neurodegenerative diseases unrelated to protein-folding disorders.

Leukotoxin binds LFA-1 on white blood cells to reduce cytokine levels and alleviate ocular inflammation without systemic side effects.

Cytophilic peptide-fused high-density lipoprotein accumulates drugs in retinal tissue via ocular instillation.

Topical eye drops containing a caspase-9 inhibitor overcome intravitreal injection aversion while reducing retinal edema.

Targeting cryptic epitopes on denatured collagen reduces toxicity from broad-spectrum anti-inflammatory drugs while inhibiting cellular interactions.

Cysteine-mediated PEG attachment on the botulinum toxin light chain extends therapeutic duration by reducing rapid degradation and renal clearance.

Removing the NFS glycosylation motif simplifies purification while point mutations boost catalytic activity, resolving homogeneity trade-offs.

An anti-Ang2 antibody binds Ang2 and Tie2 receptors to inhibit vascular leakage and choroidal angiogenesis.

Segmented S-Arrestin peptides bind MHC molecules to induce peripheral immune tolerance, avoiding broad immunosuppression side effects.

Heteroaromatic compounds modulate dopamine D1 receptors to treat schizophrenia and ADHD by resolving reliability versus adaptability contradictions.

5-substituted iminothiazine compounds inhibit BACE enzymes, reducing amyloid beta production and addressing the underlying cause of Alzheimer's disease.

GPR119 agonists activate receptors to lower blood glucose levels without hypoglycemia risk.

A wet milling method produces small organic compound particles using salts and polyols.

Propylene glycol stabilizes benzopyran derivatives in aqueous eye drops, preventing precipitation at high concentrations.

Emulsion formulation stabilizes hydrophobic cyclosporine A to improve aqueous solubility and reduce systemic absorption.

Substituted oxadiazole compounds resolve the lack of effective pharmaceutical compositions by stabilizing mitochondrial function.

Covalently modified intrinsically disordered sequence polymers induce targeted immune responses to eliminate misfolded proteins and halt disease progression.